# Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines

> **NCT00907387** · PHASE2 · COMPLETED · sponsor: **Revance Therapeutics, Inc.** · enrollment: 72 (actual)

## Conditions studied

- Lateral Canthal Lines

## Interventions

- **DRUG:** RT001
- **DRUG:** RT001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00907387
- **Lead sponsor:** Revance Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-04
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2014-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00907387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00907387, "Safety and Efficacy Study of RT001 to Treat Moderate to Severe Lateral Canthal Lines". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00907387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*